These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 11932875)

  • 1. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis.
    Hernández-Rodríguez J; García-Martínez A; Casademont J; Filella X; Esteban MJ; López-Soto A; Fernández-Solà J; Urbano-Márquez A; Grau JM; Cid MC
    Arthritis Rheum; 2002 Feb; 47(1):29-35. PubMed ID: 11932875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis.
    Hernández-Rodríguez J; Segarra M; Vilardell C; Sánchez M; García-Martínez A; Esteban MJ; Queralt C; Grau JM; Urbano-Márquez A; Palacín A; Colomer D; Cid MC
    Rheumatology (Oxford); 2004 Mar; 43(3):294-301. PubMed ID: 14679293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis.
    García-Martínez A; Hernández-Rodríguez J; Espígol-Frigolé G; Prieto-González S; Butjosa M; Segarra M; Lozano E; Cid MC
    Arthritis Care Res (Hoboken); 2010 Jun; 62(6):835-41. PubMed ID: 20535794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-Term Follow-Up Study.
    Restuccia G; Boiardi L; Cavazza A; Catanoso M; Macchioni P; Muratore F; Cimino L; Aldigeri R; Crescentini F; Pipitone N; Salvarani C
    Medicine (Baltimore); 2016 May; 95(19):e3524. PubMed ID: 27175649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease.
    Nesher G; Nesher R; Mates M; Sonnenblick M; Breuer GS
    Clin Exp Rheumatol; 2008; 26(3 Suppl 49):S30-4. PubMed ID: 18799050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.
    Mazlumzadeh M; Hunder GG; Easley KA; Calamia KT; Matteson EL; Griffing WL; Younge BR; Weyand CM; Goronzy JJ
    Arthritis Rheum; 2006 Oct; 54(10):3310-8. PubMed ID: 17009270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy.
    Hayreh SS; Zimmerman B
    Ophthalmology; 2003 Jun; 110(6):1204-15. PubMed ID: 12799248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis.
    Alba MA; García-Martínez A; Prieto-González S; Espígol-Frigolé G; Butjosa M; Tavera-Bahillo I; Rodríguez-Pintó I; Hernández-Rodríguez J; Cid MC
    Semin Arthritis Rheum; 2014 Jun; 43(6):772-7. PubMed ID: 24315461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies.
    Hayreh SS; Zimmerman B
    Ophthalmologica; 2003; 217(4):239-59. PubMed ID: 12792130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity.
    Weyand CM; Fulbright JW; Hunder GG; Evans JM; Goronzy JJ
    Arthritis Rheum; 2000 May; 43(5):1041-8. PubMed ID: 10817557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis.
    Espígol-Frigolé G; Corbera-Bellalta M; Planas-Rigol E; Lozano E; Segarra M; García-Martínez A; Prieto-González S; Hernández-Rodríguez J; Grau JM; Rahman MU; Cid MC
    Ann Rheum Dis; 2013 Sep; 72(9):1481-7. PubMed ID: 22993227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab.
    Stone JH; Tuckwell K; Dimonaco S; Klearman M; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Schulze-Koops H; Schett G; Spiera R; Unizony SH; Collinson N
    Arthritis Rheumatol; 2019 Aug; 71(8):1329-1338. PubMed ID: 30835950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silent, or masked, giant cell arteritis is associated with a strong inflammatory response and a benign short term course.
    Liozon E; Boutros-Toni F; Ly K; Loustaud-Ratti V; Soria P; Vidal E
    J Rheumatol; 2003 Jun; 30(6):1272-6. PubMed ID: 12784402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.
    Hoffman GS; Cid MC; Rendt-Zagar KE; Merkel PA; Weyand CM; Stone JH; Salvarani C; Xu W; Visvanathan S; Rahman MU;
    Ann Intern Med; 2007 May; 146(9):621-30. PubMed ID: 17470830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA).
    Spiera RF; Mitnick HJ; Kupersmith M; Richmond M; Spiera H; Peterson MG; Paget SA
    Clin Exp Rheumatol; 2001; 19(5):495-501. PubMed ID: 11579707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis.
    Salvarani C; Boiardi L; Macchioni P; Rossi F; Tartoni P; Casadei Maldini M; Mancini R; Beltrandi E; Portioli I
    Ann Rheum Dis; 1995 Aug; 54(8):640-4. PubMed ID: 7677440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: Characteristics and predictors in a long-term follow-up study.
    Muratore F; Boiardi L; Restuccia G; Cavazza A; Catanoso M; Macchioni P; Spaggiari L; Cimino L; Aldigeri R; Pipitone N; Fontana A; Casali M; Croci S; Salvarani C
    Semin Arthritis Rheum; 2020 Aug; 50(4):549-558. PubMed ID: 32446023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis.
    Jakobsson K; Jacobsson L; Mohammad AJ; Nilsson JÅ; Warrington K; Matteson EL; Turesson C
    BMC Musculoskelet Disord; 2016 Aug; 17(1):363. PubMed ID: 27558589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.
    Unizony S; Arias-Urdaneta L; Miloslavsky E; Arvikar S; Khosroshahi A; Keroack B; Stone JR; Stone JH
    Arthritis Care Res (Hoboken); 2012 Nov; 64(11):1720-9. PubMed ID: 22674883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients.
    Chevalet P; Barrier JH; Pottier P; Magadur-Joly G; Pottier MA; Hamidou M; Planchon B; El Kouri D; Connan L; Dupond JL; De Wazieres B; Dien G; Duhamel E; Grosbois B; Jego P; Le Strat A; Capdeville J; Letellier P; Agron L
    J Rheumatol; 2000 Jun; 27(6):1484-91. PubMed ID: 10852275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.